Secondline and beyond in mCRC Optimising the benefit and reducing the risk

Second-line and beyond in mCRC: Optimising the benefit and reducing the risk

06:28 EDT 9 May 2019 | ecancermedicalscience

Prof Mohamed Salem speaks to ecancer at the 2019 International Gastrointestinal, Liver and Uro-Oncology Conference (IGILUC) in Cairo about the recent advances in the treatment of metastatic colon cancer in the second-line setting and beyond. Despite...

More From BioPortfolio on "Second-line and beyond in mCRC: Optimising the benefit and reducing the risk"